205 related articles for article (PubMed ID: 36647058)
21. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
[TBL] [Abstract][Full Text] [Related]
23. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
Zong J; Xu H; Chen B; Guo Q; Xu Y; Chen C; Weng Y; Zheng W; Pan J; Lin S
Radiat Oncol; 2019 Oct; 14(1):182. PubMed ID: 31640719
[TBL] [Abstract][Full Text] [Related]
24. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
25. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
26. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of the Albumin-to-Alkaline Phosphatase Ratio before Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma.
Yang L; Gao J; Zhou Y; Tao Z; He J; Yang J; Wang R; Zhang Y; Huang Y; Zhou L; Sun B
Chemotherapy; 2021; 66(1-2):40-46. PubMed ID: 33601377
[TBL] [Abstract][Full Text] [Related]
28. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Osorio JC; Ni A; Chaft JE; Pollina R; Kasler MK; Stephens D; Rodriguez C; Cambridge L; Rizvi H; Wolchok JD; Merghoub T; Rudin CM; Fish S; Hellmann MD
Ann Oncol; 2017 Mar; 28(3):583-589. PubMed ID: 27998967
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
31. Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis.
Xiao L; Kang W; Liao J; Li Y
Braz J Otorhinolaryngol; 2022; 88 Suppl 1(Suppl 1):S70-S81. PubMed ID: 34045134
[TBL] [Abstract][Full Text] [Related]
32. [Clinical observation of thyroid-related adverse events induced by anti-PD-1 antibody SHR-1210 in patients with advanced solid tumor].
Qi L; Mo HN; Chen XL; Wang X; Wu DW; Lan B; Li Q; Wang XY; Xu JP; Yang Q; Xu BH; Huang J
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):772-775. PubMed ID: 30392342
[No Abstract] [Full Text] [Related]
33. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
Wang L; Wu Z; Xie D; Lv S; Xia L; Su Y
Radiat Oncol; 2020 Jul; 15(1):160. PubMed ID: 32615984
[TBL] [Abstract][Full Text] [Related]
34. Whole-body hyperthermia combined with chemotherapy and intensity-modulated radiotherapy for treatment of advanced nasopharyngeal carcinoma: a retrospective study with propensity score matching.
Zheng N; Xu A; Lin X; Mo Z; Xie X; Huang Z; Liang Y; Cai Z; Tan J; Shao X
Int J Hyperthermia; 2021; 38(1):1304-1312. PubMed ID: 34468276
[TBL] [Abstract][Full Text] [Related]
35. Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy.
Wang J; Lian CL; Zheng H; Lin LE; Yu YF; Lin Q; Wu SG
Oral Oncol; 2020 Dec; 111():104921. PubMed ID: 32763779
[TBL] [Abstract][Full Text] [Related]
36. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
37. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
[TBL] [Abstract][Full Text] [Related]
38. Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.
Sun XS; Liang YJ; Li XY; Liu SL; Chen QY; Tang LQ; Mai HQ
Drug Des Devel Ther; 2019; 13():3207-3216. PubMed ID: 31686783
[TBL] [Abstract][Full Text] [Related]
39. Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma.
Huang S; Wang X; Hu C; Ying H
Med Oncol; 2013 Dec; 30(4):710. PubMed ID: 23999842
[TBL] [Abstract][Full Text] [Related]
40. Current status and advances of immunotherapy in nasopharyngeal carcinoma.
Xu JY; Wei XL; Wang YQ; Wang FH
Ther Adv Med Oncol; 2022; 14():17588359221096214. PubMed ID: 35547095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
